<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655553/" ref="ordinalpos=469&amp;ncbi_uid=4903353&amp;link_uid=PMC3655553" image-link="/pmc/articles/PMC3655553/figure/F1/" class="imagepopup">Fig. 1. Schematic representation of β-AR <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> in cardiac myocytes.  From: Modulation of ?-Adrenergic Receptor <span class="highlight" style="background-color:">Signaling</span> in Heart Failure and Longevity: Targeting Adenylyl Cyclase Type 5. </a></div><br /><div class="p4l_captionBody">Upon β-AR stimulation, the Gsα subunit-bound AC produces cAMP which activates target molecules, PKA and Epac. PKA regulates Ca2+ homeostasis through SR and LTCC, increases contractility. Under conditions of excessive sympathetic stimulation, PKA-induced Ca2+ leads to hypertrophy. On the other hand, activated PKA inhibits Raf, which results in the activation of the MEK/ERK signaling, and thus suppression of apoptosis. In contrast, Epac, the other target protein of cAMP than PKA, induces myocyte apoptosis via the P38MAPK pathway. Upon activation of β2-AR, the Giβγ subunits are released and activate the PI3K/Akt pathway. Activated Akt inhibits apoptosis, and accelerates hypertrophy</div></div>